Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
Status:
Terminated
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This clinical trial is for subjects with multiple myeloma that has returned after treatment
(relapsed) or did not respond to prior treatment (refractory). The study is in two parts,
Phase I and Phase II. Phase I will determine the maximum tolerated dose of romidepsin in
combination with pomalidomide and dexamethasone. The purpose of Phase II is to evaluate the
effectiveness of combining romidepsin with pomalidomide and dexamethasone. The hypothesis is
that overall response in a cohort of patients treated with romidepsin + pomalidomide +
dexamethasone will be 60 percent.